ReviewInternational journal of molecular sciences2022
Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 201 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
201 citing papers in PubMed, 6 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale.Journal of health, population, and nutrition · 2025Pooled it
- Spleen volume in relation to ulcerative colitis and Crohn's disease: a Mendelian randomization study.Scientific reports · 2025Pooled it
- Gut microbiota and postoperative complications in colorectal surgery and its potential association with intestinal permeability and NLRP6 inflammasome.Frontiers in immunology · 2025Pooled it
- What is the link between the dietary inflammatory index and the gut microbiome? A systematic review.European journal of nutrition · 2024Pooled it
- Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Gut microbiota in chronic inflammation: the interplay with lipid mediators.Gut microbes · 2026Review
- Engineering Oral Nanoparticles: Navigating Biological Barriers in the Gastrointestinal Tract.Pharmaceutical research · 2026Review
- Review
- A Water-Soluble Curcumin Glycoside Exhibits Superior Anti-Colitic Efficacy over Native Curcumin in DSS-Induced Colitis through Anti-Inflammatory Activity and Gut Microbiota Modulation.Journal of microbiology and biotechnology · 2026Article
- Review
- Remodeling of Gut Microbiota Metabolic Function Is Associated with the Therapeutic Effects of Wenweishu Capsules in Chronic Gastritis.International journal of molecular sciences · 2026Article
- Article
- Microbiome-metabolite signaling networks in gastrointestinal disease: systems biology, network rewiring, and precision therapeutics.Archives of microbiology · 2026Review
- Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease.Journal of gastroenterology · 2026Article
- Gut Microbiota Resilience and Environmental Stressors: A Hidden Key to Lifespan Optimization?Probiotics and antimicrobial proteins · 2026Review
- In vitro modeling of inflammatory bowel diseases using a newly developed immunocompetent colon epithelial monolayer co-culture model.npj biomedical innovations · 2026Article
- Environmentally mediated interactions predict community assembly and invasion success in a gut microbiota synthetic community.mSystems · 2026Article
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
141 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Microbe-host communication is essential to maintain vital functions of a healthy host, and its disruption has been associated with several diseases, including Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD). Although individual members of the intestinal microbiota have been associated with experimental IBD, identifying microorganisms that affect disease susceptibility and phenotypes in humans remains a considerable challenge. Currently, the lack of a definition between what is healthy and what is a dysbiotic gut microbiome limits research. Nevertheless, although clear proof-of-concept of causality is still lacking, there is an increasingly evident need to understand the microbial basis of IBD at the microbial strain, genomic, epigenomic, and functional levels and in specific clinical contexts. Recent information on the role of diet and novel environmental risk factors affecting the gut microbiome has direct implications for the immune response that impacts the development of IBD. The complexity of IBD pathogenesis, involving multiple distinct elements, suggests the need for an integrative approach, likely utilizing computational modeling of molecular datasets to identify more specific therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.